Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2024

ESMO Virtual Plenary revisited

VP1-2024: RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC)

Date

13 Sep 2024

Session

ESMO Virtual Plenary revisited

Topics

Clinical Research;  Immunotherapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Dongsheng Yue

Authors

D. Yue

Author affiliations

  • Lung Cancer Dept, TMUCIH - Tianjin Medical University Cancer Institute and Hospital, 300060 - Tianjin/CN

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Introduction

Session: ESMO Virtual Plenary revisited

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.